Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical ...

Abstract/Full Text Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome Young man visiting his wife with cancer indoors ...

WEDNESDAY, July 23, 2025 (HealthDay News) -- Allogeneic hematopoietic cell transplantation (allo-HCT) is feasible in older patients with myelodysplastic syndrome, according to a study published ...

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS).